Company / Return on Equity (ROE)
Zomedica Corp. Return on Equity (ROE) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-70.9%
FY2025
5-year range
-70.9% / -6.4%
FY2022-FY2025
Trend
-195.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Zomedica Corp. reports negative total equity of -70.9% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-70.9% in FY2025 with a 3-year CAGR of -64.6%.
Declined from -14.4% to -70.9% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -64.6pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- Zomedica Corp.'s return on equity (roe) has declined for 3 consecutive years.
- In FY2025, return on equity (roe) decreased 195.5% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -70.9% | -195.5% |
| FY2024 | -24.0% | -66.9% |
| FY2023 | -14.4% | -126.3% |
| FY2022 | -6.4% | - |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026